[Calcium inhibitors: effects on cerebral blood flow and intracranial pressure].
Calcium entry blockers (CEB) have been a major advance in pharmacologic research in the last decade, especially in cardiovascular diseases. In neurology and intensive care, prescription of CEB seems to be more selective. CEB are potent cerebrovascular vasodilating drugs especially after KCL induced vasoconstriction. This property appears less evident when vasoconstriction is achieved by agonist substances. CEB act selectively on cerebral vessels, an effect which prevents the occurrence of systemic arterial hypotension. However they greatly modify the cerebrovascular response to arterial CO2. Concerning the cerebrovascular response to arterial CO2. Concerning their potential benefits in brain ischemia, it is now well admitted that CEB are useful in subarachnoid hemorrhage. Several controlled and uncontrolled human studies have demonstrated the CEB potency in vasospasm prevention and in cerebral ischemic consequences. Nonetheless when the vasospasm is installed, the benefit of the CEB appears less evident. In focal cerebral ischemia, data are few and unclear suggesting a cautious prescription of CEB. Finally CEB seem to increase intracranial pressure in humans, although this effect depends on the underlying neurologic pathology.
Payen
D
D
Lamer
C
C
Raggueneau
J L
JL
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D006801:Humans; D007427:Intracranial Pressure / Q000187:drug effects*; D010215:Papio; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy
D002121:Calcium Channel Blockers
Anti-calciques: effets sur le débit sanguin cérébral et sur la pression intracrânienne.